VSEE

VSEE is a sub-$6M micro-cap telehealth roll-up (VSee Lab + iDoc, de-SPAC'd June 2024) whose own auditor flags substantial doubt about its ability to continue as a going concern. The 10-K is explicit: an $82.4M accumulated deficit, continuing net losses, negative operating cash flow, and management's own plans required to keep the lights on. On top of that, management identified material weaknesses in internal control over financial reporting — meaning the very numbers below carry restatement risk. That combination alone puts this outside the investable set for a self-directed retail investor.

The headline — revenue $14.6M, +40.3% YoY — looks like growth until you check the quality. Gross profit rose just +2.5% ($7.36M) on that 40% revenue jump, so gross margin is collapsing as they scale: incremental revenue is coming in at near-zero contribution. Operating margin is -65.6% and net margin is -100.6% (the company lost more than a dollar for every dollar of revenue). Yes, the net loss narrowed from -$57.7M (FY2024, SPAC-related) to -$14.7M, but -$14.7M on $14.6M of sales is not a path to profitability — it's a company that must 'generate and sustain higher revenue levels' just to survive, per its own MD&A.